Singapore researchers could have a hand in developing an oral antiviral treatment for COVID-19, touted as “potentially best-in-class.” The country’s Experimental Drug Development Centre (EDDC) has signed a deal with pharma firm Everest Medicines to have what are called protease inhibitors developed into a drug. These inhibitors are molecules that can stop the coronavirus from multiplying. Dr Ang Hwee Ching, EDDC’s Deputy CEO, shared more details.
Subscribe to our channel here: https://cna.asia/youtubesub
Subscribe to our news service on Telegram: https://cna.asia/telegram
CNA Lifestyle: http://www.cnalifestyle.com